The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1580
ISSUE 1580
September 9, 2019
Issue 1580
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue. |
Drugs for Atrial Fibrillation
September 9, 2019 (Issue: 1580)
Treatment of atrial fibrillation includes anticoagulation,
rate control, and rhythm control. US guidelines were
recently updated.
... more
- CT January et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. Circulation 2019; 140:e125.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2019; March 12 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- SJ Connolly et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139.
- MR Patel et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883.
- CB Granger et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981.
- RP Giugliano et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093.
- Dabigatran etexilate (Pradaxa) – a new oral anticoagulant. Med Lett Drugs Ther 2010; 52:89.
- MR Southworth et al. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368:1272.
- FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. Available at: Available at: www.fda.gov. Accessed August 29, 2019.
- Idarucizumab (Praxbind) – an antidote for dabigatran. Med Lett Drugs Ther 2015; 57:157.
- Rivaroxaban (Xarelto) – a new oral anticoagulant. Med Lett Drugs Ther 2011; 53:65.
- Andexxa – an antidote for apixaban and rivaroxaban. Med Lett Drugs Ther 2018; 60:99.
- C Dias et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis. Am J Nephrol 2016; 43:229.
- Apixaban (Eliquis) — a new oral anticoagulant for atrial fibrillation. Med Lett Drugs Ther 2013; 55:9.
- X Wang et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol 2016; 56:628.
- Edoxaban (Savaysa) – the fourth new oral anticoagulant. Med Lett Drugs Ther 2015; 57:43.
- M Crowther et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors. Blood 2014; 124:4269.
- SJ Connolly et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380:1326.
- DR Holmes et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 2015; 65:2614.
- SM Al-Khatib et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med 2014; 160:760.
- IC Van Gelder et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362:1363.
- Safety of dronedarone (Multaq). Med Lett Drugs Ther 2011; 53:103.
- RL Woosley et al. QT drugs list. Available at: www.crediblemeds.org. Accessed August 29, 2019.
- JM Abraham et al. Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter. Circ Arrhythm Electrophysiol 2015; 8:772.
- GA Upadhyay and FJ Alenghat. Catheter ablation for atrial fibrillation in 2019. JAMA 2019; 322:686.
- HS Abed et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 2013; 310:2050.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1580
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian